Roche to cut 4,800 jobs in global restructuring plan

Thursday, December 2, 2010 11:18 AM

After absorbing Genentech, Swiss pharma giant Roche has announced its cost-cutting plans, much of which will take place in manufacturing and sales. But there will also be some significant trimming in R&D.

Roche said it will end RNA interference research in Kulmbach, Germany, Nutley, N.J., and Madison, W.I. In the product development group, Roche said only that "certain product development activities are expected to be discontinued or transferred—most of them from the U.S.—to other Roche sites or third parties to improve overall productivity. Roughly 800 positions will be affected by the planned reductions or transfers."

Roche will cut about 4,800 workers overall or about 6% of the Groups current workforce of approximately 82,000 employees, with a couple thousand more facing transfers to new locations. About 600 jobs will be cut or transferred in R&D with 640 more at stake in the company's growing diagnostics division. Company officials said the restructuring—originally announced in September—will take two years to complete. CEO Severin Schwan said Roche is taking measures to increase productivity in R&D, and would continue to look for small and medium-sized acquisitions to add to the 90 compounds in its pipeline.

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs